These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20472117)

  • 1. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
    Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
    Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
    Plewig G; Cunliffe WJ; Binder N; Höschen K
    Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women.
    Schramm GA; Schrah G
    Contraception; 2011 Oct; 84(4):390-401. PubMed ID: 21920195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
    Anthuber S; Schramm GA; Heskamp ML
    Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
    Schramm G; Heckes B
    Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg.
    Hadji P; Biskup J; Boekhoff J; Ziller M; Bonn M; Rovati L
    Contraception; 2012 Oct; 86(4):359-65. PubMed ID: 22445436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles.
    Rabe T; Hartschuh E; Wahlstrom T; Höschen K; König S
    Contraception; 2010 Oct; 82(4):358-65. PubMed ID: 20851230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice.
    Pushparajah DS; Röhm P; Höschen K; Albers D; Nowack C
    Clin Drug Investig; 2011; 31(2):121-34. PubMed ID: 21155614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW; Fisher AC; Hall N; Shangold GA
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
    Vartiainen M; de Gezelle H; Broekmeulen CJ
    Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the new antiandrogenic oral contraceptive Belara.
    Zahradnik HP; Goldberg J; Andreas JO
    Contraception; 1998 Feb; 57(2):103-9. PubMed ID: 9589837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial.
    Westhoff C; Kaunitz AM; Korver T; Sommer W; Bahamondes L; Darney P; Verhoeven C
    Obstet Gynecol; 2012 May; 119(5):989-99. PubMed ID: 22525910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
    Chaiyasit N; Taneepanichskul S
    J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.